Role of Bax in resveratrol-induced apoptosis of colorectal carcinoma cells
The natural plant polyphenol resveratrol present in some foods including grapes, wine, and peanuts, has been implicated in the inhibition, delay, and reversion of cellular events associated with heart diseases and tumorigenesis. Recent work has suggested that the cancer chemoprotective effect of the compound is primarily linked to its ability to induce cell division cycle arrest and apoptosis, the latter possibly through the activation of pro-apoptotic proteins such as Bax.
The expression, subcellular localization, and importance of Bax for resveratrol-provoked apoptosis were assessed in human HCT116 colon carcinoma cells and derivatives with both bax alleles inactivated.
Low to moderate concentrations of resveratrol induced co-localization of cellular Bax protein with mitochondria, collapse of the mitochondrial membrane potential, activation of caspases 3 and 9, and finally, apoptosis. In the absence of Bax, membrane potential collapse was delayed, and apoptosis was reduced but not absent. Resveratrol inhibited the formation of colonies by both HCT116 and HCT116 bax -/- cells.
Resveratrol at physiological doses can induce a Bax-mediated and a Bax-independent mitochondrial apoptosis. Both can limit the ability of the cells to form colonies.
KeywordsResveratrol Familial Adenomatous Polyposis HCT116 Cell Mitochondrial Apoptosis Resveratrol Treatment
Adriamycin, a potent DNA-damaging anticancer drug
5-fluorouracil, an anticancer drug affecting DNA and RNA metabolism
mitochondrial transmembrane potential, can break down upon transient or permanent permeabilization of inner MT membrane
hereditary non-polyposis colorectal cancer, the commonest form of hereditary predisposition to colorectal cancer.
Cancers claim at least six million lifes per annum worldwide, and the common and frequently therapy-resistant colon cancers are among the most notorious. Accordingly, natural food constituents capable of inhibiting, delaying or reversing events associated with tumor initiation, promotion, and progression have attracted much attention. The pharmacologically active trans form of the polyphenolic, antifungal phytoalexin resveratrol (3,5,4'-trihydroxy-trans-stilbene) is produced by more than 70 plant species and is reaching particularly high levels in grapes, peanuts and wine . A large number of publications in recent years has shown that physiological quantities of resveratrol can modulate multiple cellular pathways relevant for tumorigenesis, among them phase II drug metabolizing, cyclooxygenase, nitric oxide, DNA-synthesis, and inflammatory response, as well as cell survival, cell death and cell cycle pathways . The consensus of the many in vitro- and a limited number of in vivo-studies seems to be that micromolar quantities of the compound can not only counteract tumor initiation through anti-oxidant activities and the inhibition of enzymatic carcinogen conversion [2, 3, 4], or counteract tumor promotion through cyclooxygenase and hydroperoxidase inhibition [5, 6], but can affect tumor cell proliferation and survival through the inhibition of cell cycle, stimulation of differentiation, and induction of apoptosis [2, 3, 4]. The latter effects may be of particular relevance for the anti-tumorigenic activity of resveratrol , not least because the cell cycle/cell death machinery is specifically altered in many tumor cells and the targeting of this machinery by resveratrol opens up the possibility to specifically affect tumor cells and spare normal proliferating tissue. The compound indeed seems to possess some specificity for tumor cells .
At the level of individual proliferating cells, resveratrol appears to act primarily though the inhibition of the cell cycle [8, 9, 10, 11, 12, 13, 14]. Although apoptosis may be provoked in normal, non-transformed proliferating cells exposed to high resveratrol concentrations , a temporary, reversible cell cycle arrest in G1 and G2 phase has been reported to result at low to moderate concentrations from activation of the p53 tumor suppressor and, subsequently, from the activation of the p21Cip1 inhibitor of cyclin-dependent kinases [14, 15]. In tumor cells however, p53 function is frequently lost, and consequently, cells usually arrest in S-phase instead of G1 or G2, probably due to the inhibition of DNA synthesis by resveratrol [16, 17]. Although this cell cycle arrest is also reversible, cells with altered cell cycle checkpoints can be more prone to apoptotic death [14, 15, 18].
The precise mechanisms through which resveratrol induces apoptosis are unknown. Together, the available data point to the existence of several apoptotic pathways that can be triggered by the compound, and to the existence of survival pathways that can be inhibited by it. For example, resveratrol has been documented to be able to induce apoptosis through the activation of p53 , but also through other mechanisms in wild-type p53-deficient tumor cells . Furthermore, the compound has been shown to inhibit the activation of NFkB transcription factor which serves as a survival factor in some cell types [20, 21].
Apoptosis following resveratrol treatment has been reported to be mediated, in dependence on cell type, through the death receptor  and mitochondrial pathways [14, 23]. Recent findings make the involvement of the death receptor pathway questionable though [24, 25]. For instance, dominant-negative inhibition of this pathway failed to block apoptosis induction by a resveratrol analog . The pro-apoptotic Bax protein is one of the major players in the mitochondrion form of apoptosis , and mitochondria-mediated cell death induced by resveratrol may involve stimulation of the expression of the bax gene by p53 or other transcription factors [10, 14, 27, 28]. However, mitochondria-mediated cell death may also involve down-modulation of Bax-antagonists such as Bcl-XL or Bcl-2 , or the translocation of Bax from the cytosol to mitochondria ( and discussion therein). Since Bax was activated moderately or weakly under resveratrol in some cell types [10, 14, 27], or was activated only at high drug concentrations although apoptosis was observed at low concentrations as well , the present work was designed to address the role of Bax in colon tumor cell apoptosis more directly by studying the effect of the drug on the human HCT116 colon carcinoma cell line and a derivative in which both bax alleles were disrupted by spontaneous frameshift mutation and targeted homologous recombination .
Reagents and cell culture
Resveratrol was purchased from Alexis (San Diego, CA). JC-1 and MitoTracker Red were obtained from Molecular Probes (Eugene, OR). ADR, 5-FU, and PI were provided by Sigma (St. Louis, MO). Rabbit polyclonal antibodies Bax N-20, Bcl-XL S-18, Bcl-2 N-19, and cytochrome b were from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit polyclonal caspase 3 antibody and mouse monoclonal caspase 8 and Bax 6A7 antibodies were purchased from Transduction Laboratories/Pharmingen (San Diego, CA). The rabbit polyclonal caspase 9 antibody detecting a 36 kDa cleavage product of pro-caspase 9 was from BioVision (Mountain View, CA). Peroxidase-conjugated anti-rabbit and anti-mouse secondary antibodies, the β-actin and FITC-labeled anti-mouse monoclonal antibodies, and a liquid alkaline phosphatase detection kit were from Sigma. Stock solutions of resveratrol and Mitotracker Red were prepared in DMSO; JC-1 was dissolved in methanol; ADR, 5-FU, and PI stocks were prepared in water. The HCT116 cells and derivatives were cultured as monolayers at 37°C in a humidified 7% CO2 atmosphere in McCoy's 5A medium supplemented with 10% FCS. HT29 cells were maintained in DMEM plus 10% FCS.
Immunoblotting and subcellular fractionation
Cells were seeded in 10 cm dishes to approx. 50% confluence at 24 h before resveratrol treatment. Protein extracts were prepared by lysing the cultures in 150 μl of lysis buffer heated to 90°C and containing 50 mM Tris-HCl (pH 6.8), 100 mM DTT, 2% SDS, and 20% glycerol. Samples containing 15 or 30 μg of total cellular protein were subjected to SDS-PAGE and transferred to a nitrocellulose membrane (Immobilon-P, Millipore, Bedford, MA). Membranes were then incubated overnight with antibodies directed against β-actin (1:5,000), Bax or cytochrome b (1:500), and Bcl-XL, Bcl-2, or one of the caspases (1:200, respectively). For signal detection, the secondary anti-mouse antibody was used at a dilution of 1:5,000, and the secondary anti-rabbit antibody at 1:1,000. For the preparation of subcellular fractions, at least 107 cells were scraped off the dishes, washed with PBS, suspended in 0.5 ml fractionation buffer (20 mM HEPES pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 1 mM EGTA, 1 mM EDTA, 1 mM DTT, 0.1 mM PMSF, and 10 μg/ml each of leupeptin, aprotinin, and pepstatin A; supplemented with 250 mM sucrose), and homogenized by 10 strokes with a Dounce homogenizer. Nuclei and residual unlysed cells were pelleted at 750 g for 5 min (4°C). The high membrane (HM) fraction containing the mitochondria was harvested by centrifugation at 10,000 g for 15 min (4°C), and the supernatant was collected as the cytoplasmic fraction. The quality of all fractions was routinely tested by Western blotting with antibodies specific for nuclear proteins (anti-PCNA, p53, Rb), cytoplasmic proteins (anti-eIF4A, γ-tubulin), and mitochondrial proteins (anti-cytochrome oxidase, cytochrome b, c).
Immunofluorescence and membrane potential changes
To stain mitochondria (MT), cells were incubated with 250 nM Mitotracker Red in pre-warmed full medium for 30 min at 37°C and washed twice with full medium. For immunofluorescence, cells were washed in pre-warmed full medium and fixed for 15 min at 37°C in full medium containing 3.7% formaldehyde. The cells were then washed with PBS and permeabilized with 0.2% Triton X-100 in PBS for 5 min at room temperature. After repeated washes with PBS, cells were incubated with the primary anti-Bax antibodies (1:100) or appropriate controls for 1 h, washed twice with PBS, exposed to the secondary FITC-labeled anti-rabbit antibody (1:50), and finally examined with a Leitz fluorescence microscope. For membrane potential (ΔΨm) analysis, 2 × 105 cells were trypsinized, washed in pre-warmed medium, resuspended in McCoy's 5A medium supplemented with 0.2% FCS and JC-1 at 10 μg/ml, and incubated for 30 min at 37°C. The MT membrane potential is reflected by the quotient of red vs. green fluorescence measured by FACscanning; observation wavelengths were 530 nm for the green fluorescence and 585 nm for the red fluorescence.
FACS analysis and colony formation assay
Cells were seeded in 6-well dishes to approx. 20 % confluency 24 h prior to resveratrol treatment. Asynchronously growing cultures were harvested by trypsinization, combined with the cells floating in the medium, washed with PBS, resuspended in 100 μl of 0.9% NaCl, squeezed through a 23.5 gauge needle into 0.9 ml of methanol and fixed for 30 min at -20°C. Cells were then repeatedly washed with PBS, resuspended in PBS supplemented with RNase A (25 μg/ml) at approx. 106 cells/ml, and stained with PI (25 μg/ml) for at least 1.5 h at 4°C in the dark. DNA fluorescence was measured with a Becton Dickinson FACScan (Bedford, MA); the Cell Quest software (Becton) was employed for data acquisition and analysis. Cells with a less-than-2n DNA content were apoptotic. For colony formation assays, initially 1.5×, 3×, and 4.5 × 103 live cells, counted with a CASY cell counter, were seeded in 25 cm2 tissue culture flasks and incubated for approx. 10 days until colonies formed. Since untreated bax -/- cultures were able to produce approx. 5× more colonies than the parental HCT116 cells, the numbers of seeded live cells were adjusted to produce equal colony numbers for the drug treatment experiments. Colonies were fixed with 0.25 % glutaraldehyde and stained with crystal violet.
Treatment of the cells with 100 μM resveratrol for 24 h resulted in the redistribution of Bax, regardless of p53-status, producing a distinctive, punctuate staining pattern in the cytosol with perinuclear concentration, resembling the pattern produced by the mitochondria-specific Mitotracker Red dye (Figure 2A). Confocal imaging confirmed that a fraction of the Bax immunofluorescence merged with the mitochondrial staining; however, a proportion of Bax appeared not to co-localize with the mitochondria (Figure 2B). Furthermore, when cultures were treated with resveratrol and were separated into cell fractions after 24 h, Bax protein accumulated in the high membrane fractions enriched for mitochondria, again regardless of p53-status (Figure 2C). Finally, when we studied the response to 100 μM resveratrol of human HT29 colon carcinoma cells expressing the dysfunctional p53-273H mutant, HT29 like HCT116 cells showed co-localization of Bax with mitochondria and underwent apoptotic cell death upon drug treatment (data not shown), demonstrating that this effect is not limited to one cell line and is indeed wild-type p53 independent. Together, these results demonstrate that active cellular Bax in colon cancer cells co-localizes with the mitochondria in response to resveratrol exposure, independently of the p53 tumor suppressor.
Resveratrol has been documented to cause apoptosis in a large number of tumor cell lines in vitro[8, 14, 19, 22, 33], in a rat model of azoxymethane induced colon carcinogenesis , and in a mouse model of familial adenomatous polyposis . The effects of the drug on cell survival are mediated through the activation of downstream effectors such as caspase 3 via two major initiator pathways, the death receptor and the mitochondrial pathway. Although the Fas death receptor pathway has been implicated in some forms of resveratrol-induced apoptosis [22, 35], many solid tumors seem to be affected exclusively through the mitochondrial pathway [14, 23], which intimately involves the Bcl-2 protein family members of cell survival regulators including the anti-apoptotic Bcl-2 and Bcl-XL, and the pro-apoptotic BH-123 protein Bax . Recent work has shown that Bax can be an important mediator of anticancer drug-induced cell death. For example, nonsteroidal anti-inflammatory drugs (NSAIDs) cause Bax-dependent apoptosis in human HCT116 colon carcinoma cells . In this system, the NSAID-provoked cell death was associated with a downregulation of Bax-antagonist Bcl-XL. In other model systems, Bax was overproduced in response to drugs, including resveratrol [10, 14]. We have shown in the present paper that a further Bax-dependent mechanism of resveratrol-induced apoptosis may be active – aside from alterations of the Bax:Bcl-XL or Bax:Bcl-2 ratios by Bax overproduction or antagonist downregulation: the subcellular redistribution of present Bax protein. Since Bax expression was stimulated only at high resveratrol concentrations while Bax translocation and mitochondria-mediated cell death were observed also at low concentrations, we asked what relevance Bax might have for the chemopreventive activity of the compound.
Our results show that the lack of Bax in HCT116 colon carcinoma cells attenuates but fails to completely inhibit the resveratrol-induced mitochondrial form of apoptosis. This finding is in accord with a recent report showing that stable overexpression of Bax-antagonist Bcl-2 in U937 cells reduces, but does not prevent, resveratrol-provoked death . Along the same line, HCT116 bax -/- cells exhibited a reduced sensitivity to apoptosis induction by the anticancer drug 5-FU, but were not completely resistant like they were in response to the NSAID sulindac . One function of Bax and the related BH-123 protein Bak is the induction of mitochondrial outer membrane permeability, which eventually results in the activation of apoptosis-executing caspases. Cells from mice deficient for both Bax and Bak, but not cells deficient for one or the other only, are almost completely resistant to mitochondria-mediated apoptosis , suggesting that these proteins have redundant functions in this pathway. Bak is robustly expressed in HCT116 cells, and recent work has shown that bax-deficient HCT116 cells are more sensitive to apoptosis-provoking drugs such as ceramide than other bax-deficient cells . Whether Bak complements the lack of Bax in HCT116 bax -/- cells treated with resveratrol remains to be seen; however, recent observations with isolated rat mitochondria indicate that the drug is also able to contribute directly to the opening of the mitochondrial permeability transition pore complex and thereby induce the collapse of ΔΨm without involving the Bax/Bak proteins . Combined, the available data thus indicate that the chemopreventive agent resveratrol can affect the survival of tumor cells through several different pathways.
Most colorectal tumor cell lines apparently show decreases in the ratio of the pro-apoptotic Bax and the anti-apoptotic Bcl-XL, and recent observations suggest that mutational inactivation of the bax gene may be frequent in the HNPCC-predisposition to colorectal cancer and may render these cancers resistant to important cancer chemopreventives such as the NSAIDs . The natural plant polyphenol resveratrol, in contrast, can trigger several different mitochondrial apoptosis pathways, and has actually been demonstrated to prevent the formation of colon tumors and reduce the formation of small intestinal tumors by 70% in a mouse model of familial adenomatous polyposis . One might therefore consider resveratrol or derivatives of it, possibly in combination with other drugs, as a chemopreventive approach to the management of patients with hereditary predispositions to colorectal cancer.
Low to moderate doses of the natural cancer chemopreventive ingredient of some foods, resveratrol, induce mitochondrial apoptosis but fail to stimulate Bax expression or alter the Bax:Bcl-XL ratio in human HCT116 colon carcinoma cells. Instead, the compound induces co-localization of active Bax protein with the mitochondria. HCT116 cells with both bax alleles inactivated undergo mitochondrial apoptosis in response to resveratrol less efficiently than the parental cells, yet cell death through the mitochondrial pathway is not completely inhibited. Thus, resveratrol can activate Bax-dependent and -independent forms of mitochondrial apoptosis. Both forms can independently limit the formation of colonies.
We thank Bert Vogelstein for the HCT116 cell lines. This research was supported by a grant from the German Research Foundation (DFG) to K.R.
- 5.Mutoh M, Takahashi M, Fukuda K, Matsushima Hibiya Y, Mutoh H, Sugimura T, et al: Suppression of cyclooxygenase-2 promoter-dependent transcriptional activity in colon cancer cells by chemopreventive agents with a resorcin-type structure. Carcinogenesis. 2000, 21: 959-963. 10.1093/carcin/21.5.959.CrossRefPubMedGoogle Scholar
- 9.Hsieh TC, Juan G, Darzynkiewicz Z, Wu JM: Resveratrol increases nitric oxide synthase, induces accumulation of p53 and p21(WAF1/CIP1), and suppresses cultured bovine pulmonary artery endothelial cell proliferation by perturbing progression through S and G2. Cancer Res. 1999, 59: 2596-2601.PubMedGoogle Scholar
- 13.Park JW, Choi YJ, Jang MA, Lee YS, Jun DY, Suh SI, et al: Chemopreventive agent resveratrol, a natural product derived from grapes, reversibly inhibits progression through S and G2 phases of the cell cycle in U937 cells. Cancer Lett. 2001, 163: 43-49. 10.1016/S0304-3835(00)00658-3.CrossRefPubMedGoogle Scholar
- 24.Wieder T, Prokop A, Bagci B, Essmann F, Bernicke D, Schulze Osthoff K, et al: Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary, leukemic lymphoblasts. Leukemia. 2001, 15: 1735-1742.CrossRefPubMedGoogle Scholar
- 27.Lu J, Ho CH, Ghai G, Chen KY: Resveratrol analog, 3,4,5,4'-tetrahydroxystilbene, differentially induces pro-apoptotic p53/Bax gene expression and inhibits the growth of transformed cells but not their normal counterparts. Carcinogenesis. 2001, 22: 321-328. 10.1093/carcin/22.2.321.CrossRefPubMedGoogle Scholar
- 30.Makin GWJ, Corfe BM, Griffiths GJ, Thistlethwaite A, Hickman JA, Dive C: Damage-induced Bax N-terminal change, translocation to mitochondria and formation of Bax dimers/complexes occur regardless of cell fate. EMBO J. 2001, 20: 6306-6315. 10.1093/emboj/20.22.6306.CrossRefPubMedPubMedCentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/2/27/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.